Skip to content

Dyne Therapeutics, Inc. DYN Payments Of Debt Issuance Costs

Payments Of Debt Issuance Costs at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
Scholar Rock logo
Scholar RockSRRK
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$3.35B+153%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfDebtIssuanceCosts.

The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dyne Therapeutics, Inc.'s payments of debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dyne Therapeutics, Inc.'s payments of debt issuance costs?
Dyne Therapeutics, Inc. (DYN) reported payments of debt issuance costs of $30K in Q1 2026.